Form 4: Adaptimmune Therapeutics Director Acquires Options to Purchase Over 1.2 Million Ordinary Shares

Lawrence M. Alleva, a director of Adaptimmune Therapeutics PLC, reported acquiring options to purchase 1,213,926 ordinary shares on July 1, 2024.

Summary

• On July 1, 2024, Lawrence M. Alleva, a director of Adaptimmune Therapeutics PLC, filed a Form 4.
• The form reports the acquisition of options to purchase 1,213,926 ordinary shares.
• The exercise price of the options is $0.16, converted from GBP0.13 based on an exchange rate of $U.S. 1.263714 to GBP1.00.
• The options are exercisable from July 1, 2025, and expire on July 1, 2034.
• Following the transaction, Alleva directly owns 1,213,926 derivative securities.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. The acquisition of options by a director could be seen as a slightly positive sign, but it's not definitive.

Positives

• A director's acquisition of options may signal confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if interpreted as a sign of confidence from a company director.

Key Dates